We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Bioengineering Breakthrough to Improve Bone Regeneration Treatments

By HospiMedica International staff writers
Posted on 12 Jun 2024
Print article
Image: The bioengineering breakthrough helps repair damaged bones without causing negative side effects (Photo courtesy of Dhawan, et al.; https://doi.org/10.1002/adma.202310789)
Image: The bioengineering breakthrough helps repair damaged bones without causing negative side effects (Photo courtesy of Dhawan, et al.; https://doi.org/10.1002/adma.202310789)

Growth factor therapies, which involve the targeted delivery of specific proteins to stimulate tissue regeneration, are promising techniques for enhancing the body's natural healing processes. However, these therapies can lead to significant side effects when applied to bone healing. To be effective, active proteins must be administered in high concentrations at the site of bone fractures or defects. This can result in uncontrolled growth factor release, leading to ectopic bone formation, where bone grows in unintended places. Additionally, these treatments can trigger postoperative inflammation, adversely affecting patients' health.

In a significant bioengineering advancement, researchers at the University of Glasgow (Glasgow, Scotland) have discovered a novel approach to utilize growth factors for bone repair without the adverse effects associated with previous methods, promising improved outcomes for patients. This innovation could pave the way for developing new therapeutic options for individuals with severe skeletal injuries or cancer patients needing to regenerate bone tissue lost to illness.

The team employed a cost-effective polymer known as poly(ethyl acrylate), or PEA, to create a surgical implant suitable for use in bone defects. The implant's surface possesses unique properties that allow it to bind the body’s inactive growth factors, activating them only at the necessary site. The researchers tested the efficacy of these implants in mice with significant bone defects and observed complete regeneration of the bone and controlled bone formation in the targeted areas throughout the study. The findings of the study were published in Advanced Materials on June 6, 2024

“The biological processes that underpin this study have been understood for more than two decades, but this is the first time that they’ve been harnessed to produce this regenerative effect,” said Dr. Udesh Dhawan, Research Fellow at the University of Glasgow’s James Watt School of Engineering. “Being able to deliver immobilized proteins directly to the treatment site in this way provides much more control over how growth factors become active and start the healing process. It also works at much lower concentrations than previous treatments, helping further minimize the chances of unwanted bone growth beyond the site in need of healing.”

Related Links:
University of Glasgow 

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Cylindrical Water Scanning System
SunSCAN 3D
New
Mattress Replacement System
Apollo Infant Dynamic

Print article

Channels

Surgical Techniques

view channel
Image: The Trilogy Valve with locator technology is the only TAVI system approved for aortic regurgitation (Photo courtesy of JenaValve)

New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation

Aortic regurgitation is a condition in which the aortic valve does not close properly, allowing blood to flow backward into the left ventricle. This results in decreased blood flow from the heart to the... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.